ClinicalTrials.gg
Not yet recruitingNCT06668051Updated Oct 31, 2024

Determination of Functional Exercise Capacity, Respiratory Muscle Endurance in Idiopathic Pulmonary Fibrosis

An observational study in Idiopathic Pulmonary Fibrosis and Healthy, sponsored by Hacettepe University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by Hacettepe University · Observational

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
24
Ages
18 Years and older
Sex
All
01

Study summary

There are not enough studies in the literature comparing functional capacity, respiratory functions and muscle strength of IPF patients with healthy individuals. This study aims to compare functional capacity, respiratory functions and muscle strength of IPF patients with healthy individuals.

02

Conditions studied

  • Idiopathic Pulmonary Fibrosis
  • Healthy

Keywords

  • Quality of life
  • Muscle strength
  • Respiratory function tests
  • Pulmonary fibrosis
03

In context

Idiopathic Pulmonary Fibrosis

565 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 117 are open to participants now.

This study's planned enrollment of 24 is below the median of 156 across 155 observational studies indexed under Idiopathic Pulmonary Fibrosis.

Browse Idiopathic Pulmonary Fibrosis studies →

Lead sponsor

Hacettepe University is the lead sponsor of 1,001 studies on the registry; 215 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

12 patients with IPF will be included in the patient group. Twelve healthy individuals, similar in age and gender to the patient group, will be included in the study as a control group.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being over 18 years old
  • having a clinical, radiological and/or pathological diagnosis of IPF
  • volunteering to participate in the study
  • not having had a respiratory tract infection in the last month
  • not having an accompanying airway disease such as COPD
  • being in the stable phase of the disease

Exclusion criteria

Exclusion Criteria:

  • Patients who have had an IPF attack within the last three months and/or are in the acute exacerbation of the disease; who use a walking aid; who have unstable angina or class III-IV heart failure according to the New York Heart Association congestive heart failure classification; who have orthopedic, neuromuscular, neurological and cardiac diseases that may affect walking and balance; who have serious comorbid conditions such as cancer or neoplasm; who have a history of sarcoidosis, tuberculosis, emphysema and/or lung surgery; who have communication problems, mental and cognitive problems, and who cannot adapt to the applied assessment methods will be excluded from the study.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
24 participants (estimated)
Patient registry
No

Groups and cohorts

  • IPF

    Inclusion Criteria: Being over 18 years old -having a clinical, radiological and/or pathological diagnosis of IPF -volunteering to participate in the study -not having had a respiratory tract infection in the last month -not having an accompanying airway disease such as COPD -being in the stable phase of the disease Exclusion Criteria: Patients who have had an IPF attack within the last three months and/or are in the acute exacerbation of the disease; who use a walking aid; who have unstable angina or class III-IV heart failure according to the New York Heart Association congestive heart failure classification; who have orthopedic, neuromuscular, neurological and cardiac diseases that may affect walking and balance; who have serious comorbid conditions such as cancer or neoplasm; who have a history of sarcoidosis, tuberculosis, emphysema and/or lung surgery; who have communication problems, mental and cognitive problems, and who cannot adapt to the applied assessment methods will be

  • HEALTHY GROUP

    Being over 18 years old -having a clinical, radiological and/or pathological volunteering to participate in the study -not having had a respiratory tract infection in the last month -not having an accompanying airway disease such as COPD

06

What researchers measure

Primary outcomes

  1. 6 Minute Walk Test (6MWT)

    6 MWT is a submaximal test that evaluates the functional exercise capacity of individuals. Individuals will walk along a 30-meter corridor at their maximum speed. Individuals will be asked to walk as much distance as possible within the given time without running or jumping.The time will be started as soon as individuals start walking. Before and after the test, O2 saturation with pulse oximeter, heart rate, dyspnea and fatigue severity with Borg scale will be evaluated between 0 and 10 points (0; no symptoms, 10; most severe symptoms). Individuals will be asked to stop the test if they do not feel well during the test. When the time is up, participants will be asked to leave the sign given for marking purposes on the ground and the walking distance will be evaluated with the sign.

    Time frame: 1 month

  2. 6 Minute Pegboard and Ring Test

    This test will be used to measure upper extremity function. The test will be performed using a Pegboard with two upper and two lower pegs placed at the patients shoulder level and above shoulder level (20 cm). Ten rings will be placed on each lower peg. During the test, patients move each of the rings on the lower pegs to the upper pegs using both hands simultaneously, and then move the rings back from the upper pegs to the lower pegs. The goal is to move as many rings as possible for six minutes. The score will be reported as the number of rings moved simultaneously. Patients will be allowed to stop and rest during the test if they experience severe shortness of breath, fatigue, or other discomfort, and to resume moving the rings as soon as possible. Scores will be measured for heart rate, blood pressure, perception of dyspnea, and upper extremity fatigue before and immediately after each test.

    Time frame: 1 month

  3. 30-second sit to stand test

    This test reflects the strength of the lower extremities. The individual sits in the middle of a chair with no armrests and a sitting height of 43 cm, with his back straight and straight, his arms crossed in front, and his feet touching the floor. With the start command, he stands up and sits down completely. The individual who learns the test with a stopwatch is asked to sit down and stand up for 30 seconds and the score obtained is recorded as the number of repetitions in the evaluation form.

    Time frame: 1 month

  4. Forced Vital Capasity

    Forced vital capacity (FVC) is the volume of air that is exhaled quickly and forcefully following a deep inspiration. It is a pulmonary function test parameter and performed using spirometry. The best value obtained from three technically acceptable measurements is expressed as a percentage of the expected value calculated from age, gender and height.

    Time frame: 1 month

  5. Respiratory Muscle Strength Assessment

    Respiratory muscle strength will be determined by measuring the maximal inspiratory pressure (MIP) created in the mouth using a mouth pressure device and the maximum expiratory pressure (MEP) with personal antibacterial and antiviral disposable filters. During the MIP measurement, the patient is asked to make a maximum expiration, and the patient\'s nose is closed with a clip and then the patient\'s nose is closed with a clip and then the patient is asked to make a maximum inspiration for 1-3 seconds. During the MEP measurement, the patient is asked to make a maximum inspiration, and the patient\'s nose is closed with a clip and then the patient\'s nose is closed with a clip and then the patient\'s nose is closed with a clip and then the tests are repeated until no further improvement is observed and there is no difference of more than 5% between the 2 best values.

    Time frame: 1 month

  6. Respiratory Muscle Endurance Test

    It is applied at 60% of maximal inspiratory pressure. After the device is placed in the mouth, the nose is closed with a clamp. The patient is asked to breathe in and out through the mouth for 10 minutes. Before starting the test, patients are informed that if they feel too much shortness of breath during the test, they can remove the device and the test will end in this way. Before and after the test, the SpO2 value is measured with a portable pulse oximeter attached to the finger; dyspnea perception is measured and recorded with the Modified Borg Scale.

    Time frame: 1 month

  7. Hand Grip Strength

    A Jamar Hydraulic Hand Dynamometer (Jamar Hydraulic Hand Dynamometer, Cedarburg, England) will be used to measure hand grip strength. The Jamar hand dynamometer is considered the most reliable tool for measuring grip strength. Individuals are asked to sit with the shoulder adducted, the elbow flexed at 90°, the forearm in the middle position, and the wrist in a neutral position. Participants are asked to hold the handle and squeeze with the maximum force they can. The measurement begins with the dominant hand. Three consecutive measurements are taken for the dominant and non-dominant hands, with a 1-minute interval between measurements. The highest value of the three measurements is recorded.

    Time frame: 1 month

  8. Quadriceps Strength

    Measurements will be made with a portable digital muscle strength tester (01165 manual muscle tester, Lafayette Instrument Co. Lafayette, USA) to evaluate knee extensor muscle strength. It will be applied while individuals are in a sitting position on the edge of the bed with their knees bent to 90° and the space between the back of the knee and the bed filled with a towel. Individuals are asked to cross their hands on their chest and sit with their bodies upright. When the test begins, the knee is bent and the knee is straightened. The researcher measures the knee extensor muscle strength by applying force slightly above the ankle and trying to push downward in order to overcome the straight knee force. The test is repeated three times to measure the right and left knee extensor muscle strength and the highest value obtained is recorded in kilograms (kg) and Newtons (N).

    Time frame: 1 month

  9. Respiratory Function Testing

    It is performed using a spirometer. The best value obtained from three technically acceptable measurements is expressed as a percentage of the expected value calculated from age, gender and height. The patient must be in an upright sitting position during the test.

    Time frame: 1 month

  10. Forced expiratory volume in 1 second

    forced expiratory volume in 1 second (FEV1) is the volume of air exhaled in the first second from the beginning of the forced vital capacity maneuver. In general, it provides information about the restriction in the large airways. It is a pulmonary function test parameter and performed using spirometry. The best value obtained from three technically acceptable measurements is expressed as a percentage of the expected value calculated from age, gender and height.

    Time frame: 1 month

  11. Forced expiratory flow between 25 and 75% of vital capacity (FEF 25-75)

    Forced expiratory flow between 25 and 75% of vital capacity (FEF 25-75) is the average flow rate at 50% of the forced vital capacity maneuver. It provides information about the obstruction in medium and small bronchi. It is a pulmonary function test parameter and performed using spirometry. The best value obtained from three technically acceptable measurements is expressed as a percentage of the expected value calculated from age, gender and height.

    Time frame: 1 month

  12. Peak expiratory flow

    Peak expiratory flow (PEF) is measured with a maximum inspiration followed by a maximum exhalation maneuver. It provides information about obstruction in the large airways. It is a pulmonary function test parameter and performed using spirometry. The best value obtained from three technically acceptable measurements is expressed as a percentage of the expected value calculated from age, gender and height.

    Time frame: 1 month

  13. FEV1/FVC

    A low FEV1/FVC ratio (\<80%) is used as a primary obstruction parameter. It is a pulmonary function test parameter and performed using spirometry. The best value obtained from three technically acceptable measurements is expressed as a percentage of the expected value calculated from age, gender and height.

    Time frame: 1 month

Secondary outcomes

  1. TAMPA KINESOPHOBIA SCALE

    TAMPA KINESOPHOBIA SCALE is a 17-question scale developed to measure fear of movement/re-injury (150). The scale includes parameters of injury, re-injury and avoidance-fear in physical activities related to daily life and work. It is a Likert-type 4-point scale (1=strongly disagree, 2=disagree, 3=agree, 4=strongly agree). In this questionnaire, where a maximum score of 68 and a minimum score of 17 are obtained; a score greater than 37 is classified as high-degree kinesiophobia, and a score equal to or lower is classified as low-degree kinesiophobia.

    Time frame: 1 month

  2. LEICESTER COUGH QUESTIONNAIRE

    The Leicester cough questionnaire is a short, easy-to-apply, valid questionnaire developed to investigate the effect of chronic cough on quality of life. It includes 3 areas and 19 topics: physical, psychological and social. In this questionnaire, patients answer the questions themselves; they select the topics they identify as problems and rank them according to the importance attributed to them. The topics are divided into areas using clinical logic. A seven-point Likert scale is used for evaluation.The score for each area is calculated by dividing the patient's total score for each question by the number of questions. The score for each area ranges from 1 to 7. The total score is the sum of the 3 areas (physical, psychological and social) The total score range is 3 to 7. A higher score indicates a better health status. .

    Time frame: 1 month

  3. St. George's Respiratory Questionnaire (SQRQ)

    St. George's Respiratory Questionnaire (SQRQ): The effects of the disease on quality of life are examined in 3 sections: symptoms, activity and impact. SGRQ consists of 76 questions. It has a scale of 0 to 100 points. Zero indicates good health status, 100 indicates the worst disease status

    Time frame: 1 month

  4. Bouchard Three-Day Physical Activity Record

    Bouchard Three-Day Physical Activity Record: Bouchard's physical activity diary is an example of a widely used activity record in which participants report their activities every 15 minutes. Activities are rated from 1 to 9 (1 = sedentary, 9 = vigorous/vigorous activity) to obtain a total energy expenditure score. The resulting numbers are added together and multiplied by the MET values to calculate the estimated daily energy expenditure (kcal/kg1).

    Time frame: 1 month

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2024; primary completion for Jan 2025, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2024
First posted
Oct 31, 2024
StartEst.
Nov 20, 2024
Primary completionEst.
Jan 22, 2025
CompletionEst.
Feb 22, 2025
Last update
Oct 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06668051
Responsible party
Bilge Gore (physiotherapist, Hacettepe University) — Principal investigator
First posted
Oct 31, 2024
Start date
Nov 20, 2024 (estimated)
Primary completion
Jan 22, 2025 (estimated)
Completion
Feb 22, 2025 (estimated)
Last update
Oct 31, 2024

Study contacts

Bilge GORE
Contact
bilgegore98@gmail.com
+903123052525 ext. 178

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion